Genemod, a Seattle, WA-based cloud-based workspace collaboration software for biopharma R&D teams, today announced it raised $4.5 million in seed funding.
The round was co-led by defy. vc and LDV Partners, with participation from Dolby Family Ventures and Vulcan/Cercano Ventures.
"We believe that scientists must be empowered with tools to discover and develop medicines and ultimately get them to market faster than ever before," said Jacob Lee, CEO and co-founder of Genemod. "That's why we built Genemod – to transform the way biopharma companies operate."
Legacy R&D software and other traditional methods are decentralized, disorganized, and inefficient, ultimately resulting in higher healthcare costs. Genemod is working to be the solution to this problem by building a dynamic cloud-based research platform designed for research teams to house their entire R&D lifecycle: from data acquisition and project documentation to inventory management and reporting.
Genemod is also working to solve the "reproducibility crisis": an ongoing phenomenon that continues to plague research scientists.
Company: Genemod, Inc.
Raised: $4.5M
Round: Seed Round
Funding Month: May 2023
Lead Investors: defy. vc and LDV Partners
Additional Investors: Dolby Family Ventures and Vulcan/Cercano Ventures
Company Website: https://www.genemod.net/
Software Category: Workspace Collaboration Software
About the Company: Genemod is a cloud-based workspace collaboration software for biopharma R&D teams. Genemod accelerates life sciences R&D by improving collaboration for every team in a hybrid workspace so that scientists can work on big ideas, without the busywork. In the past year, Genemod has expanded into the biopharma R&D space working with teams from startups to enterprise companies including AstraZeneca, Bristol-Myers, Merck, and more. The company's mission is to empower teams to create the next breakthrough.
Source: https://www.prnewswire.com/news-releases/genemod-raises-4-5m-to-become-the-central-research-platform-for-biopharma-companies-301815437.html